Kyntra Bio Statistics
Total Valuation
Kyntra Bio has a market cap or net worth of $28.53 million. The enterprise value is -$40.97 million.
Important Dates
The next estimated earnings date is Monday, May 4, 2026, after market close.
| Earnings Date | May 4, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Kyntra Bio has 4.05 million shares outstanding. The number of shares has increased by 1.02% in one year.
| Current Share Class | 4.05M |
| Shares Outstanding | 4.05M |
| Shares Change (YoY) | +1.02% |
| Shares Change (QoQ) | +0.05% |
| Owned by Insiders (%) | 2.08% |
| Owned by Institutions (%) | 17.71% |
| Float | 3.56M |
Valuation Ratios
The trailing PE ratio is 0.16.
| PE Ratio | 0.16 |
| Forward PE | n/a |
| PS Ratio | 4.42 |
| Forward PS | 5.39 |
| PB Ratio | 6.36 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 3.39, with a Debt / Equity ratio of 4.37.
| Current Ratio | 3.39 |
| Quick Ratio | 3.19 |
| Debt / Equity | 4.37 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -5.18 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -16.96% |
| Return on Invested Capital (ROIC) | n/a |
| Return on Capital Employed (ROCE) | -50.18% |
| Weighted Average Cost of Capital (WACC) | 19.88% |
| Revenue Per Employee | $189,412 |
| Profits Per Employee | $5.40M |
| Employee Count | 34 |
| Asset Turnover | 0.04 |
| Inventory Turnover | 6.98 |
Taxes
| Income Tax | -90,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -9.73% in the last 52 weeks. The beta is 0.90, so Kyntra Bio's price volatility has been similar to the market average.
| Beta (5Y) | 0.90 |
| 52-Week Price Change | -9.73% |
| 50-Day Moving Average | 7.13 |
| 200-Day Moving Average | 8.96 |
| Relative Strength Index (RSI) | 48.86 |
| Average Volume (20 Days) | 12,379 |
Short Selling Information
The latest short interest is 112,826, so 2.79% of the outstanding shares have been sold short.
| Short Interest | 112,826 |
| Short Previous Month | 113,876 |
| Short % of Shares Out | 2.79% |
| Short % of Float | 3.17% |
| Short Ratio (days to cover) | 3.86 |
Income Statement
In the last 12 months, Kyntra Bio had revenue of $6.44 million and earned $183.45 million in profits. Earnings per share was $45.38.
| Revenue | 6.44M |
| Gross Profit | -17.63M |
| Operating Income | -45.34M |
| Pretax Income | -58.29M |
| Net Income | 183.45M |
| EBITDA | -44.59M |
| EBIT | -45.34M |
| Earnings Per Share (EPS) | $45.38 |
Full Income StatementBalance Sheet
The company has $88.98 million in cash and $19.56 million in debt, giving a net cash position of $69.42 million or $17.15 per share.
| Cash & Cash Equivalents | 88.98M |
| Total Debt | 19.56M |
| Net Cash | 69.42M |
| Net Cash Per Share | $17.15 |
| Equity (Book Value) | 4.48M |
| Book Value Per Share | -7.42 |
| Working Capital | 69.83M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$4.77 million and capital expenditures -$38,000, giving a free cash flow of -$4.81 million.
| Operating Cash Flow | -4.77M |
| Capital Expenditures | -38,000 |
| Depreciation & Amortization | 748,000 |
| Net Borrowing | -80.56M |
| Free Cash Flow | -4.81M |
| FCF Per Share | -$1.19 |
Full Cash Flow StatementMargins
Gross margin is -273.80%, with operating and profit margins of -704.07% and 2,848.63%.
| Gross Margin | -273.80% |
| Operating Margin | -704.07% |
| Pretax Margin | -905.19% |
| Profit Margin | 2,848.63% |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |